Targeting RAS in Pancreatic Cancer: Is the "Undruggable" Era Finally Over?

For decades, targeting RAS in pancreatic cancer was deemed "undruggable"—until now. With groundbreaking Phase 3 RASOLUTE trial data shaking up #ASCO26 , are next-generation pan-RAS inhibitors finally delivering the breakthrough clinicians and patients have been waiting for? Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/targeting-ras-in-... In this episode we break down the emerging science, biomarker-driven strategies, and toxicity management behind the novel pan-RAS inhibitor, daraxonrasib. Discover how these biology-driven designs are moving past old limitations to expand options for advanced pancreatic cancer care. What You’ll Learn in This Episode: ● From "Undruggable" to Opportunity: How broader strategies, like pan-RAS inhibitors, are expanding treatment options for more patients. ● Clinical Trial Spotlight: Early signals from the phase 3 RASOLUTE trial evaluating the investigational pan-RAS inhibitor daraxonrasib. ● Biomarker Testing & Patient Selection: Why comprehensive molecular profiling (somatic, liquid, and germline) is essential at advanced diagnosis. ● Managing Toxicities: How to interpret preliminary data and proactively manage gastrointestinal and dermatologic side effects. ● The Future of RAS Therapy: Why treatment strategies must remain grounded in tumor biology to build effective combination therapies. Chapter Timestamps: 00:00 – Introduction: Shifting the Paradigm in Pancreatic Cancer 01:10 – Overcoming the "Undruggable" Barrier of RAS Mutations 03:25 – Phase 3 RASOLUTE Trial: Early Efficacy Data for Daraxonrasib 05:40 – Biomarker Strategies: Tissue-Based vs. Liquid Biopsies 07:55 – Toxicity Management: Navigating GI and Skin Adverse Events 10:15 – Clinical Trial Implementation and Real-World Considerations 12:30 – Future Outlook: Biology-Driven Design and Combination Therapies About the Speakers: Christos Fountzilas, MD, FACP: A Gastrointestinal Medical Oncologist and early-phase clinical trial investigator at ‪@roswellparkofficial‬. Waqas Haque, MD, MPH: A Hematology/Oncology Fellow at the ‪@UChicago‬ specializing in innovative clinical trial design, value-based care delivery, and clinical investigation. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData #PancreaticCancer #Oncology #PanRAS #TargetedTherapy #Daraxonrasib #BiomarkerTesting #ClinicalTrials #GIOncology #MedicalEducation #CancerResearch #MedEd #Podcast #asco26 #asco